IRB Brokerage: Citi Rating: Buy Target: Rs 238 Rationale: The management has said it does not see any impact of the recent events on its business or bid for projects. While the business fundamentals remain unchanged, the news flow around this issue could remain a near-term overhang on the stock.
Exide Brokerage: Merrill Lynch Rating: Buy Target: Rs 144 Rationale: Earnings disappointed due to a weaker EBITDA margin lead by high cost inventory and price discounts. They have reduced their FY14 EPS estimate by 12%.
Cipla Brokerage: CLSA Rating: Outperform Target: Rs 360 Rationale: They believe Cipla is likely to deliver a strong operating performance in the coming quarter particularly on Lexapro supplies to Teva and a weakening currency.
Marico Brokerage: Standard Chartered Rating: Outperform Target: Rs 203 Rationale: Strong volume lad sales growth was a positive in Marico’s financial performance in the fourth quarter. Despite a sharp increase in ad spends the company has posted a strong 37% growth in EBITDA and remains our top pick.